Trial Profile
Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Hyperlipidaemia; Hyperlipoproteinaemia type V
- Focus Therapeutic Use
- Sponsors Kowa Research Institute
- 06 May 2021 Status changed from discontinued to withdrawn prior to enrolment.
- 21 Jun 2016 New trial record